Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn’s Disease Intestinal Mucosa: Analysis From the CELEST Study
Daniel Aguilar(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Azucena Salas(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Núria Planell(Instituto de Salud Carlos III), Heath Guay(AbbVie (United States)), Alba Garrido-Trigo(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Lluís Revilla Sancho(Instituto de Salud Carlos III), Míriam Esteller(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Ana P. Lacerda(AbbVie (United States)), James W. Butler(AbbVie (United States)), Juan José Lozano(Instituto de Salud Carlos III), J. Wade Davis(AbbVie (United States)), Julián Panés(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Cited by 30
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
|The Lancet|2022|383
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus
|Endoscopy|2009|332
Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease
|Nature Communications|2023|280